| Metric | Value | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 1.9K Cr | 8.4% | 40.1% |
| Total Income | 2.0K Cr | 8.5% | 37.0% |
| Expenditure | 1.8K Cr | 4.6% | 32.8% |
| PBT | 181.06 Cr | 34.9% | 99.2% |
| Net Profit | 162.91 Cr | 37.6% | 92.5% |
| OPM | 7.38% | 3.21pp | 4.83pp |
| NPM | 8.22% | 3.84pp | 2.37pp |
| EPS | 3.53 | 37.5% | 90.8% |
Profitability Acceleration — Can FY27 Target of ₹1,000 Cr PAT Stay on Track?
PB Fintech reports Q1 FY-2027 results on August 5, 2026 with eyes on whether margin expansion and recurring premium growth sustain the path to ₹1,000 Cr full-year profit.
What to Expect
~₹200–250 Cr
On-plan for FY27 ₹1,000 Cr target; FY26 full-year was ₹670 Cr
~₹7,200–7,600 Cr
Assume 30%+ YoY growth (health segment driver). FY26 full-year: ₹29,934 Cr
30%+ YoY
The key profitability lever — lower acquisition cost, higher margins
Expected expansion
PAT growth (40–50%) outpacing revenue growth reflects mix shift to renewals
A strong print shows PAT growth tracking or beating the 40–50% range, renewal premium acceleration above 30%, and health segment momentum continuing (66% growth was seen in Q1 FY26). A weak print would signal margin pressure despite revenue growth, a slowdown in renewal momentum, or new business mix deterioration, pushing the full-year ₹1,000 Cr target into question.
On Track?
PB Fintech explicitly guided for ₹1,000 Cr PAT in FY27 at its analyst day in May 2026 — a 49% uplift from FY26's ₹670 Cr. Q1 FY26 delivered ₹169–170 Cr PAT (inferred from 41% net income growth and ₹1,348 Cr revenue); if Q1 FY27 achieves ₹200–250 Cr, the trajectory remains credible. The company's real edge is recurring renewal revenue — every policy that renews cuts acquisition cost and lifts operating leverage. Premium growth of 42% in FY26 was driven 57% by new protection premiums, but renewal momentum is the ceiling on margin expansion.
What the Street Says
Since Last Quarter
Ownership moves: HDFC Mutual Fund disclosed a 5.02% stake (July 2026). MacRitchie (linked to early VC backers) sold 2.46% via block trade at ₹1,751 in May — a partial exit near prior highs. FII holding has ticked down 83 bps to 39.94% (Q4 FY26 vs Q3); DII in-flow of 719 bps suggests domestic asset managers are building.
Corporate action: ₹20 Cr capital infusion approved into wholly-owned subsidiary PB Pay (₹13 Cr deployed by June 30). This is strategic — digital payments are a growth vector beyond insurance, and management signalled its conviction on the bet.
Tax order (not a surprise, but watch the appeal): Paisabazaar received a CIT(A) order confirming ₹145.91 Cr disallowance across two prior years (FY22–23: ₹85.60 Cr; FY21–22: ₹60.31 Cr) on expenses under Section 37 of the I-T Act. Company plans to appeal. No financial impact provisioned yet — the order is appealable and brought-forward losses may offset part of the claim. This is a 2–3 year tail-risk, not a near-term earnings headwind.
Management: Two independent directors (Kaushik Dutta, Lilian Jessie Paul) completed their first term and did not seek reappointment (June 2026). Board remains functional; no red flags on governance.
The Setup
PB Fintech is at an infra inflection — it has crossed into consistent profitability and is now scaling the margin narrative. The ₹1,000 Cr FY27 PAT target is achievable if Q1 lands in the 40–50% growth zone and renewal momentum sustains the 30%+ trajectory. Street sees 22% upside to the stock at ₹1,955 consensus, premised on execution of this target and proof of operating leverage. Analysts are Buy-weighted (17/24), but coverage is thin on quarterly granularity — results day will sharpen conviction.
Three things to watch: (1) Renewal premium growth rate — does it hold 30%+, or is the margin lift a one-time mix benefit? (2) Health segment traction — 66% growth in Q1 FY26 was the standout; does it persist or normalize? (3) Operating expense control — with scale, does SG&A deleverage, or does growth in new geographies / products eat into margin? A beat on margin with clear guidance to ₹1,000 Cr is the catalyst. A miss signals the need to reset expectations.
Boom to Fade: The GST Tailwind Rolls Off
PB Fintech's 40% revenue growth and 92% PAT surge reflect a Q1 FY26 base lifted by exceptional GST demand—now acknowledged as already fading. Sequential deterioration and guidance deflation reveal a quarter in transition, not inflection.
₹163 Cr
+92.5% YoY
-37.6%
QoQ collapse
-8.4% QoQ
post-GST spike
8.2% actual
vs 9% stated
PB Fintech's headline numbers look exceptional—40% revenue growth, 92% PAT surge—until you zoom out. The base quarters (Q1 FY26) benefited from an exceptional GST demand spike that management now openly acknowledges is already fading in Q1 FY27. The real story is the sequential slide: revenue down 8.4% quarter-on-quarter, PAT down 37.6%. This is not a growth acceleration; it's a cycle rolling off, with the tailwind already in the rear-view mirror by the time results were filed.
Claims vs. reality: the fact-check
Revenue ₹1,888 Cr (+40% YoY); PAT ₹163 Cr (+92.5% YoY)
₹1,888.3 Cr, ₹162.9 Cr—numbers are precise
Supported
PAT margin improved from 6% to 9% YoY
Delivered NPM 8.2%, not 9%. Margin improvement is 220 bps, not 300 bps
Overstated by 80 bps
Paisabazaar targeting ₹100 Cr EBITDA; progressing well
Management: 'Maybe at about half of that.' Implies ~₹50 Cr annual guidance. Broke even Q1 but ramp slower than prior commentary ('significantly profitable')
Contradicted (50% guidance cut)
GST-driven demand surge continuing through the year
Q3/Q4 FY26 saw spike; Q1 FY27 'already started to fade'; Q2 'uncertain'
Contradicted
Fresh business growth at all-time highs; strong momentum
Fresh growth will be lower than renewals (55% LTM); sequential revenue down 8.4% signals deceleration
Overstated
What changed
Where growth is coming from—and where it's stalling
Insurance (Core)
+41% YoY
Health +59%, term +53% vs market ~20%. Driven by affordability innovation (monthly mode 30%, maternity 3-mo wait). 82% new-to-insurance. Real TAM, not just GST demand.
Premium GWP ₹8,372 Cr
Renewals (LTM)
+55% YoY
Now growth lead vs fresh. Will compound over time without marketing spend. Stickiness is the new moat.
Trail ₹1,003 Cr
Credit (Core)
+33% disbursals
Re-entering growth post-slowdown. Volume momentum restored but secondary to insurance focus.
Revenue +25% YoY
POSP (Partner channel)
+46% YoY
1.13 Lac partners (+55%). Top 100 at 16% share; management targeting concentration reduction. Tier 2/3 outpacing Tier 1.
Premium ₹1,637 Cr
Paisabazaar
Q1 breakeven
Operationally breakeven like Policybazaar. EBITDA ramp slower than promised. Daily SIP + Bonds launches won't move needle for 2+ years.
Contribution margin 41%
PB Health
Target ₹500 Cr by Mar'27
Ambitious ramp needed in 2 quarters. Fitterfly revenue 4x post-acq but healthcare execution is hard. High risk.
Quarterly loss ₹7 Cr
The bull case and the bear case
Bull: Renewals at 55% LTM provide stable, non-cyclical growth base independent of demand spikes
Bull: Tier 2/Tier 3 now 65–70% of online business; penetration upside still large in India's insurance TAM
Bull: AI now touches 30–40% of 10 Cr monthly interactions; productivity gains in sales, risk, service automation are material
Bull: 5-year revenue CAGR 51% (₹238 Cr Q1 FY22 → ₹1,888 Cr Q1 FY27); platform moat deepening with data and tech
Bear: Sequential PAT -37.6% QoQ despite headline YoY strength—signals cyclicality and tailwind dependency
Bear: GST demand exceptional, now fading; fresh business will decelerate; next structural tailwind unclear
Bear: Paisabazaar EBITDA halved (₹100→₹50 Cr) without proactive disclosure; credibility gap widens
Bear: PAT margin claimed 9%, delivered 8.2%—80 bps over-statement on a headline metric
Bear: PB Health ramp to ₹500 Cr run-rate + breakeven by Mar'27 is steep; healthcare execution is hard
Bear: Regulatory commission-change and dark-patterns scrutiny create policy uncertainty for broker model
Ranked risks: what should concern a holder
Fresh growth deceleration + guidance miss
HighManagement acknowledged fresh growth 'won't be as high' as renewals. If fresh drops below 20%, renewals must sustain 40%+ to hit 30% group guidance—high bar. If both moderate, full-year target breaks.
GST tailwind has officially faded
HighQ3/Q4 were 'special' demand. Q1 already fading; Q2 uncertain. No visibility to next regulatory tailwind. Base-case growth should revert to 25–30%, implying current YoY comps aren't repeatable.
Paisabazaar profitability ramp slower than promised
HighEBITDA halved (₹100→₹50 Cr) without proactive disclosure. Q1 breakeven is progress, but path to ₹50 Cr annual will take quarters. SIP/Bonds launches won't materialize revenue for 2+ years. Drag on group EBITDA persists.
Regulatory commission cuts or dark-patterns enforcement
Medium-HighRegulator discussing effort-based commission changes (asymmetric by channel). Phone-collection dark-patterns debate ongoing. Broker model legally protected but outcomes uncertain. Commission cuts = margin squeeze.
Margin expansion stalls despite top-line growth
MediumManagement not pursuing short-term efficiency; increasing acquisition spend. If fresh-growth ROI weakens (due to deceleration), acquisition spend doesn't compound, and margin leverage evaporates.
PB Health ramp to ₹500 Cr by Mar'27 misses
MediumCurrently ₹28 Cr annualized loss (~₹7 Cr quarterly). Target requires ₹125 Cr quarterly run-rate by Q4. Hospital approvals positive but healthcare execution is unpredictable. Miss rerates consensus lower.
Overbought technical setup; profit-taking risk
Low-MediumRSI 74.9 after +7.35% day-5 pop. Stock 11.36% below ATH but momentum-driven. If sequential softness returns in Q2, technical unwind risk is material (5–10% downside possible).
How the street is positioned—and what it's pricing in
Pre-result, the stock closed at ₹1,620 (Aug 5). The day-1 reaction was negative (−1.3%), but reversed into a +7.35% pop by day 5, reaching ₹1,741 by Aug 14. The market has chosen to reward the YoY numbers and the long-term structural thesis over the sequential deterioration. This rebound signals the street is pricing in a recovery narrative: that fresh growth will stabilize post-GST fade, renewals will sustain 40%+, and the 30% guidance holds. That's an optimistic but not unreasonable read if you believe Tier 2/3 penetration and renewal stickiness are as durable as the 51% 5-year CAGR suggests.
Institutional flows tell a more cautious story: FII ownership fell 2.64 percentage points to 37.30% (from 39.94% prior quarter), signalling selective selling by overseas funds. Domestic investors (DII) added 3.69 percentage points to 40.42%, reflecting domestic confidence in the structural thesis. Critically, CEO Yashish Dahiya sold 4,00,000 shares @ ₹1,751 on May 29—a large insider liquidation near the all-time high of ₹1,964.2. While not a direct bearish signal, it suggests management viewed fair value near the highs as a liquidity window, consistent with a 'take profits here' posture.
Technically, the stock sits 11.36% below ATH but above its 20-, 50-, and 200-day SMAs, with overbought RSI (74.9). The recovery has been real, but momentum-based entries now carry repricing risk if Q2 data shows renewed sequential softness or guidance cuts. Valuation assumes 30% growth is delivered with renewals as the ballast. Any evidence that renewals moderate below 45% or fresh stays sub-20% would break that assumption and trigger downside repricing.
What to watch next: three concrete catalysts
1 · H2 fresh growth stabilization
Management reaffirmed 30% growth but explicitly acknowledged fresh deceleration. Q2/Q3 fresh-growth YoY will be the test. If fresh stays above 30%, 30% guidance holds. If fresh slides to 20–25%, renewals must sustain 40%+ to bridge the gap—achievable but leaves no room for error. Track quarterly new business growth rate as the north star metric.
2 · Paisabazaar quarterly EBITDA trend
Q1 breakeven was a milestone, but the path to ₹50 Cr annual guidance (~₹12.5 Cr quarterly) is steep. Watch Q2/Q3 results for operating leverage. If quarterly EBITDA lingers at ₹5–8 Cr, annual run-rate is tracking to ₹30–35 Cr, not ₹50 Cr, signalling further guidance cuts ahead.
3 · PB Health run-rate progress toward ₹500 Cr by Mar'27
Currently ₹7 Cr quarterly loss. Target is ₹125 Cr quarterly run-rate by Q4 FY27 + breakeven. Hospital billing approvals and Fitterfly 4x revenue are positive, but Q2/Q3 quarterly run-rate vs. ₹500 Cr implied target will reveal execution risk. Miss here signals healthcare scaling challenges.
The honest read
Verdict: Hold. PB Fintech delivered on YoY headline numbers but the quarter is a transition, not an inflection. The 40% revenue and 92% PAT growth are impressive in absolute terms but anchored to a Q1 FY26 base enriched by an exceptional GST demand surge—now openly acknowledged as fading. Sequential deterioration (revenue −8.4% QoQ, PAT −37.6% QoQ) is the real signal; the tailwind is rolling off.
Management's execution on long-term structurals is credible: renewals at 55% LTM growth, Tier 2/3 penetration at 65–70% and accelerating, AI touching 30–40% of interactions with measurable productivity gains. These validate the platform thesis and moat. But credibility took hits this quarter that matter: Paisabazaar EBITDA halved without proactive disclosure, PAT margin claimed at 9% but delivered 8.2% (80 bps over-statement), fresh growth now explicitly capped below renewals, and the CEO sold 4,00,000 shares near the highs. These are not terminal red flags individually, but collectively they suggest management is managing expectations downward as cyclical headwinds (GST fade) bite.
The market's +7.35% day-5 rebound and continued strength (now ₹1,741, RSI 74.9) prices in a recovery assumption: that fresh growth stabilizes above 25%, renewals stay at 40%+, and the 30% full-year guidance is achieved. That thesis is valid if Tier 2/3 penetration and renewal stickiness are as structural and durable as the 5-year 51% CAGR implies. But if Q2/Q3 show renewed sequential softness, fresh growth trending below 20%, or renewals moderating to 35–40%, repricing downside becomes likely and material (5–10% or more from current levels).
This is steady execution in transition, not a step-change inflection. The single number to track from here is renewal revenue growth (LTM basis). If renewals sustain at 45%+ and fresh stabilizes above 25%, the 30% group guidance holds and the structural thesis continues to compound. If renewals drop to 35–40% or fresh slides below 20%, guidance misses are material and the stock rerated lower. Paisabazaar and PB Health are secondary; renewals are the ballast. Watch Q2 and H2 for clarity.
Strong YoY growth masks sequential deterioration; GST tailwind fading
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Prior ~30% growth guidance reaffirmed but with caveats on fresh growth deceleration. Paisabazaar EBITDA guidance halved—a material miss vs. prior commentary on 'significantly profitable' upcoming year.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
PB Fintech delivered strong YoY growth (40% revenue, 92% PAT) on GST-driven demand surge that is now fading. Sequential deterioration (revenue -8.4%, PAT -37.6% QoQ) and Paisabazaar EBITDA guidance cut from ~₹100 Cr to ~₹50 Cr signal deceleration ahead. Long-term structurals remain intact—market opportunity, renewal acceleration to 55%+ LTM, Tier 2/3 penetration—but near-term momentum is rolling off. Management reaffirmed ~30% growth but acknowledged fresh business will trail renewals.
₹1888.3 Cr
Revenue · +40.1% YoY₹162.9 Cr
Reported PAT · +92.5% YoYExpanding
Margins · vs guidance: MixedDid the claims hold up?
Revenue grew 40%, PAT grew 92% YoY to ₹163 Cr
METRevenue ₹1888.3 Cr (+40.1%), PAT ₹162.9 Cr (+92.5%)
PAT margin improved from 6% to 9% YoY
OVERSTATEDDelivered NPM 8.2%, not 9%. Margin did expand but claim overstates actual.
Paisabazaar EBITDA faring well, targeting ₹100 Cr annually
MISSManagement stated 'maybe at about half of that' = ~₹50 Cr, down from prior guidance
GST-driven demand surge continuing through year
MISSQ3/Q4 FY26 saw big demand, Q1 FY27 'already started to fade', uncertain for Q2. Tailwind is eroding.
Strong momentum across group with fresh growth at all-time highs
OVERSTATEDRevenue -8.4% QoQ, PAT -37.6% QoQ. Fresh growth will be lower than renewal growth going forward.
Earnings quality
What changed since the last call
Paisabazaar EBITDA guidance halved
DowngradePrior guidance ~₹100 Cr annually (implied from 'significantly profitable' commentary), now ~₹50 Cr. 50% cut.
Fresh business growth capped
DowngradeManagement stated fresh growth 'won't be as high' as 50%+ renewal growth. Implies deceleration from prior 39-48% run-rate.
GST demand normalizing
DowngradeQ3/Q4 FY26 saw surge, Q1 FY27 'already started to fade', uncertain for Q2. Tailwind acknowledged as short-term only.
AI productivity gains now material
Upgrade30-40% of 10 Cr monthly interactions now AI-touched; sales productivity, risk screening, service automation showing wins.
Tier 2/3 penetration accelerating
UpgradeNow 65-70% of online business vs earlier lower mix. South growing faster than North. Market share gains in underpenetrated geographies.
The Q&A
Analysts pressed on growth sustainability, regulatory headwinds, and margin path. Management held firm on long-term vision but conceded near-term headwinds (GST fade, fresh growth deceleration). Deflected on dark patterns regulation and specific COR model economics. Tone measured, not defensive.
Growth outperformance — Sachin Salgaonkar, BofA
AnsweredThree drivers: aggressive demand creation & marketing spend; attractively priced, tailored products; superior claims service. 82% of inflow is new-to-insurance. Monthly mode (30% of health) and maternity innovation (3-month vs 1-2yr waiting) driving affordability.
Margin trajectory — Sachin Salgaonkar, BofA
AnsweredRenewals growth will beat fresh for 12 months+, but we're increasing acquisition spend. Not pursuing short-term efficiency; targeting lifetime value. Margin expansion will come from growth, not contraction at lower growth.
Regulatory commission risk — Sachin Salgaonkar, BofA
PartialLegally, broker must put maximum effort per regulator. We've had two demand spikes (COVID, GST) that faded. Effort required to sell insurance is high—we make 1-2% margin after 18 years. If anyone can do better, welcome. Don't anticipate major change.
Claims servicing scale — Prayesh Jain, Motilal
AnsweredSupporting 100% of claims that reach us. ~1.25-1.67% of base claims per quarter, ~6% annually. Settlement is complex; most claims self-resolve; we're a fallback for stuck/disputed claims. Effort-intensive per claim.
Motor growth outlook — Prayesh Jain, Motilal
AnsweredMotor + two-wheeler direct grew >30%, POSP grew ~50%. Dependent on new car/bike sales; we're rollover player. Gaining share modestly each quarter. Will continue.
PB Health progress — Prayesh Jain, Motilal
AnsweredJust approved second hospital billing. Fitterfly revenue up 4x since acquisition. Internal targets: ₹500 Cr annual run-rate by Mar'27, break-even. Opened 1-2 hospitals from scratch, others in pipeline. One year in; healthcare is complex but working.
Savings softness — Dipanjan Ghosh, Citi
AnsweredFresh growth 20% despite choppy markets. Two developments: (1) Waiver of Premium concept expanded beyond children—60%+ of domestic business now in July; (2) GIFT City launch Sept 2025—dollar plans, non-residents repurchasing. Both positive for forward growth.
Paisabazaar monetization — Dipanjan Ghosh, Citi
PartialDaily SIP for self-employed (lower monthly income visibility). No pilot; learning from Policybazaar. Industry growing 20-22% YoY. Won't be >5-10% of Paisa revenue in 2 years, possibly 10-15% at best. Savings stickiness-building, not revenue-building short-term.
Paisabazaar EBITDA — Jayant Kharote, Axis Capital
DodgedMaybe at about half of that [~₹50 Cr]. Broke even in Q1. [Implicit 50% guidance cut from prior ₹100 Cr annual target.]
AI monetization — Jayant Kharote, Axis Capital
AnsweredOperating system restructure ongoing. 30-40% of 10 Cr monthly interactions now AI-touched. Sales productivity gains (advisors see relevant info in real-time), risk screening (saved ₹10k Cr sum assured), service automation (20-30% interactions auto-handled). Focus on outcomes, not token burn. Goal: A+ customer experience.
Dark patterns & phone collection — Manas Agrawal, Bernstein
DefensiveNo deception; phone number requirement is transparent on first page. Generating enquiries is high-effort; phone is essential. UK market (MoneySuperMarket, Confused.com) also collect without dark pattern concerns. Will let courts decide if any issue arises.
H2 fresh growth — Manas Agrawal, Bernstein
PartialQ3 was above-trend due to GST. We target 30% growth and have beaten it historically. Will maintain above-market growth. Not calling it slowdown; goal is consistent above-market performance.
Expense leverage — Shreya Shivani, Nomura
AnsweredRevenue grew 40-46%, costs grew ~35%. No particular cost reduction effort yet. 'Haven't started to fight yet'—efficiency will come later. Q1 is weakest quarter; hired 5,000 people gross in Q1 despite seasonality. Not optimizing for cost yet.
POSP concentration — Supratim Datta, ICICI Securities
AnsweredReducing top 100 concentration by expanding partner base (1.2-1.4 Lac partners vs ~12 Lac total GI agents). Focus is scale, not profitability. Willing to invest as long as it's an investment in capability, not expense.
Motor TP policy period extension — Supratim Datta, ICICI Securities
PartialBrand new ticket sizes will go up (good for new players). Real opportunity if enforcement rises (per judgment, fuel not sold without TP insurance, etc). If enforcement is high like 2019 post-Motor Vehicle Act, meaningful jump possible. Too early to call.
Paisabazaar EBITDA reset — Jayant Kharote, Axis Capital
DodgedWe broke even [in Q1]. Didn't directly answer full-year, but context of 'maybe half' implies ~₹50 Cr annual guidance, revised down from prior ₹100 Cr.
Guidance
~30% growth target reaffirmed; history of exceeding
MediumPrior guidance maintained but with caveats. Fresh growth will decelerate post-GST tailwind fade. Q3 FY26 was 'above trend' demand spike.
Margin expansion from lifetime value reinvestment; no near-term target
MediumManagement stated not pursuing short-term efficiency; increasing acquisition spend. PAT margin 8.2% delivered (vs 9% claimed) suggests limited near-term expansion.
Risks the call surfaced
Demand cyclicality
HighGST-driven demand surge in Q3/Q4 FY26 is 'already starting to fade' in Q1 FY27. Q2 outlook 'uncertain'. Management acknowledged insurance demand is 'extremely low' and dependent on regulatory tailwinds.
Regulatory/Policy
HighRegulator discussing effort-based commission cuts, potentially asymmetric by channel (banks vs aggregators vs manufacturers). Separate dark patterns debate on phone number collection for quotes. Management deflected but acknowledged uncertainty.
Profitability guidance
HighPrior guidance: ~₹100 Cr EBITDA annually for Paisabazaar. Management now states 'maybe at about half of that' = ~₹50 Cr. 50% reduction not proactively communicated; investor had to ask.
Sequential volatility
MediumPAT ₹162.9 Cr down 37.6% QoQ; revenue down 8.4% QoQ. Signals sharp seasonality and cyclicality. Q1 is weakest quarter of year but magnitude of decline is notable.
Margin pressure
MediumManagement stated PAT margin improved to 9%, but delivered NPM is 8.2%—an 80 bps gap. Margin expansion story may be overstated. Management stated increasing acquisition spend; margins won't expand significantly near-term.
Management
Score 7/10. Articulate, direct answers to most questions. Willing to acknowledge headwinds (GST fade, demand softness). Deflected on regulatory specifics and Paisabazaar EBITDA initially (investor had to probe). Met YoY guidance (40% growth vs ~30% target). Paisabazaar EBITDA halved from prior ~₹100 Cr to ~₹50 Cr—material miss on profitability ramp. Renewal growth 55% LTM tracking well; fresh deceleration flagged.
1 · H2 FY27
Post-GST tailwind fade recovery test; fresh growth stabilization
2 · Sep 2026
Paisabazaar daily SIP launch; Bonds platform on PB Money
3 · Mar 2027
PB Health ₹500 Cr run-rate + breakeven milestone target
Management reaffirmed ~30% growth but acknowledged fresh business will trail renewals.